Ontario Teachers Pension Plan Board Has $1.28 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Ontario Teachers Pension Plan Board raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 95.0% during the fourth quarter, Holdings Channel reports. The firm owned 3,617 shares of the biotechnology company’s stock after buying an additional 1,762 shares during the period. Ontario Teachers Pension Plan Board’s holdings in United Therapeutics were worth $1,276,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of UTHR. Cerity Partners LLC boosted its stake in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $4,098,000 after buying an additional 2,702 shares in the last quarter. Milestone Asset Management LLC boosted its stake in shares of United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 1,037 shares in the last quarter. Korea Investment CORP grew its holdings in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock worth $13,863,000 after purchasing an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after purchasing an additional 789 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after purchasing an additional 50,291 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Up 0.2 %

UTHR stock opened at $284.82 on Wednesday. The business has a fifty day moving average of $320.45 and a 200-day moving average of $350.12. The company has a market cap of $12.79 billion, a P/E ratio of 12.51, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a twelve month low of $230.39 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period in the prior year, the company posted $4.36 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on UTHR. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $955,319.67. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of the business’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $285.16, for a total value of $855,480.00. Following the transaction, the director now owns 1,750 shares of the company’s stock, valued at $499,030. The trade was a 63.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 80,500 shares of company stock valued at $27,849,960. 11.90% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.